Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
drugs
fda
3
×
life sciences
national blog main
national top stories
new york blog main
3
×
new york top stories
san diego blog main
san diego top stories
biotech
boston
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
akcea therapeutics
alder biopharmaceutical
allergan
alnylam pharmaceuticals
american academy of neurology
amgen
antibiotics
arvinas
astrazeneca
What
make
3
×
drug
fda
way
alnylam
approval
approves
arguments
big
biotechs
cells
chose
class
close
commercialized
companies
company
competitors
decades
device
drugs
ema
employ
europe
firms
follows
gene
harmful
hits
interference
ipo
ipos
life
medical
medicine
meeting
method
migraine
mute
neuro
Language
Current search:
make
×
fda
×
" new york blog main "
×
@xconomy.com
4 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
